Congress has a ‘time-limited window’ to shake up drug pricing, employers, health groups saynews2021-07-14T13:35:51+00:00July 14th, 2021|Fierce Pharma|
That $56,000 price on Biogen’s Aduhelm? It doesn’t factor waste that could total $2B annually: expertnews2021-07-14T11:40:32+00:00July 14th, 2021|Fierce Pharma|
AstraZeneca clears final antitrust hurdle as $39B Alexion buy wins U.K. nodnews2021-07-14T10:07:03+00:00July 14th, 2021|Fierce Pharma|
Nkarta keeps natural killer therapy ball rolling with plans for new San Francisco headquarters, manufacturing sitenews2021-07-13T20:50:13+00:00July 13th, 2021|Fierce Pharma|
So far, so not-so-good: Neurologists slow to warm up to Biogen’s Alzheimer drug Aduhelm, study findsnews2021-07-13T20:15:17+00:00July 13th, 2021|Fierce Pharma|
So far, not so good: Neurologists slow to warm up to Biogen’s Alzheimer drug Aduhelm, study findsnews2021-07-13T20:15:17+00:00July 13th, 2021|Fierce Pharma|
All aboard the Cell Shuttle: Cellares’ cell therapy factory-in-a-box project attracts a 3rd partner in Poseidanews2021-07-13T18:54:36+00:00July 13th, 2021|Fierce Pharma|
Sanofi, Lilly, Novo and a trio of PBMs face racketeering claims over pricey insulin drugsnews2021-07-13T15:36:58+00:00July 13th, 2021|Fierce Pharma|
Florida judge rules for generic, over-the-counter manufacturers of Zantac knockoffs, backing preemption claimnews2021-07-13T15:25:03+00:00July 13th, 2021|Fierce Pharma|
Biogen’s Aduhelm probe in Congress escalates as lawmakers ask for info on FDA meetings, pricing tacticsnews2021-07-13T15:24:48+00:00July 13th, 2021|Fierce Pharma|
